{"url_path":"/sec/tnxp/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-11","source_url":"https://www.sec.gov/Archives/edgar/data/1430306/0001999371-26-010486-index.html","accession_number":"0001999371-26-010486","cik":"0001430306","ticker":"TNXP","issuer_name":"Tonix Pharmaceuticals Holding Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1430306/0001999371-26-010486-index.html","primary_entity_key":"0001430306","primary_entity_name":"Tonix Pharmaceuticals Holding Corp."},"word_count":61,"has_tables":true,"body_markdown":"**Item 5. Other Information**\n\n*Rule 10b5-1 Trading Arrangements and\nNon-Rule 10b5-1 Trading Arrangements*\n\nDuring the fiscal quarter ended March\n31, 2026, none of our officers or directors, as those terms are defined in Rule 16a-1(f), adopted\nor terminated\na “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as those terms are defined\nin Item 408 of Regulation S-K.\n\n \n\n34"}